The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

A definitive model for predicting absolute risk of coronary heart disease (CHD) in male and female people with Type II diabetes is not yet available. This paper provides an equation for estimating the risk of new CHD events in people with Type II diabetes, based on data from 4540 U.K. Prospective Diabetes Study male and female patients. Unlike previously published risk equations, the model is diabetes-specific and incorporates glycaemia, systolic blood pressure and lipid levels as risk factors, in addition to age, sex, ethnic group, smoking status and time since diagnosis of diabetes. All variables included in the final model were statistically significant (P<0.001, except smoking for which P=0.0013) in likelihood ratio testing. This model provides the estimates of CHD risk required by current guidelines for the primary prevention of CHD in Type II diabetes.

[1]  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. , 1985, British medical journal.

[2]  W. Kannel.  Silent myocardial ischemia and infarction: insights from the Framingham Study. , 1986, Cardiology clinics.

[3]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[4]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[5]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.

[6]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[7]  J. Manson,et al.  A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. , 1991, Archives of internal medicine.

[8]  B. Dahlöf,et al.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) , 1991, The Lancet.

[9]  E. Barrett-Connor,et al.  Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. , 1991, JAMA.

[10]  J. Huttunen,et al.  Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study , 1992, Diabetes Care.

[11]  M. Hughes,et al.  Regression dilution in the proportional hazards model. , 1993, Biometrics.

[12]  R. H. Eaton,et al.  A Pilot Scheme for Improving the Accuracy of Serum Cholesterol Measurement in Scotland and Northern Ireland , 1993, Annals of clinical biochemistry.

[13]  David Collett.  Modelling Survival Data in Medical Research , 1994 .

[14]  R. Holman,et al.  UK Prospective Diabetes Study (UKPDS) XI: Biochemical Risk Factors in Type 2 Diabetic Patients at Diagnosis Compared with Age‐matched Normal Subjects , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[15]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice , 1994 .

[16]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[17]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[18]  L. Ramsay,et al.  Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table , 1996, The Lancet.

[19]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[20]  A. Zbrozek,et al.  Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.

[21]  R. Holman,et al.  Approach to maintaining comparability of biochemical data during long-term clinical trials. , 1997, Clinical chemistry.

[22]  R. Holman,et al.  U.K. Prospective Diabetes Study 22: Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM , 1997, Diabetes Care.

[23]  A. Zbrozek,et al.  Model of Complications of NIDDM: I. Model construction and assumptions , 1997, Diabetes Care.

[24]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[25]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[26]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[27]  S M Grundy,et al.  Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. , 1998, Circulation.

[28]  Philip D. Harvey,et al.  Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.

[29]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[30]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[31]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[32]  L. Coupal,et al.  Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. , 1998, Archives of internal medicine.

[33]  M D Feher,et al.  Prediction of cardiovascular risk , 1999, BMJ.

[34]  M. Feher,et al.  Lipid modification and coronary heart disease in type 2 diabetes: different from the general population? , 1999, Heart.

[35]  Barry Lewis,et al.  Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[36]  L. Coupal,et al.  Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated? , 2000, Circulation.

[37]  A J Palmer,et al.  The Mt. Hood challenge: cross-testing two diabetes simulation models. , 2000, Diabetes research and clinical practice.

[38]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[39]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[40]  M Aickin,et al.  The global diabetes model: user friendly version 3.0. , 2000, Diabetes research and clinical practice.

[41]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[42]  Paul Fenn,et al.  Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) , 2000, BMJ : British Medical Journal.

[43]  R. Holman,et al.  Life-expectancy projection by modelling and computer simulation (UKPDS 46). , 2000, Diabetes research and clinical practice.

[44]  J. French,et al.  Using the Framingham model to predict heart disease in the United Kingdom: retrospective study , 2000, BMJ : British Medical Journal.

[45]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[46]  S. Thompson,et al.  Correcting for regression dilution bias: comparison of methods for a single predictor variable , 2000 .

[47]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[48]  K. Airaksinen.  Silent coronary artery disease in diabetes – a feature of autonomic neuropathy or accelerated atherosclerosis? , 2001, Diabetologia.

[49]  N. Wareham,et al.  Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) , 2001, BMJ : British Medical Journal.

[50]  R. Holman,et al.  Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51) , 2001, Diabetologia.

[51]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.